Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 30;7(9):FSO745.
doi: 10.2144/fsoa-2021-0051. eCollection 2021 Oct.

Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study

Octavian Sabin Tătaru  1 , Orsolya Martha  2 , Felice Crocetto  3 , Biagio Barone  3 , Septimiu Voidazan  4 , Angela Borda  5 , Anca Sin  6 , Adina Hutanu  7 , Andrada Loghin  5 , Ileana Sin  6 , Daniel Porav-Hodade  2 , Calin Bogdan Chibelean  2 , Liliana Vartolomei  1 , Giuseppe Lucarelli  8 , Matteo Ferro  9 , Virgil Gheorghe Osan  1 , Carlo Buonerba  10 , Mihai Dorin Vartolomei  6
Affiliations

Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study

Octavian Sabin Tătaru et al. Future Sci OA. .

Abstract

Aim: This study aims to investigate any modification of serological FSCN1 in prostate cancer patients compared with patients without neoplasia.

Material & methods: Clinical data and blood specimens from patients with and without prostate cancer were obtained. A quantitative sandwich ELISA method was used to determine serological values of FSCN1.

Results: Although serum values of FSCN1 were dissimilar in the two cohorts of patients (6.90 vs 7.33 ng/ml), the difference was not statistically significant (p = 0.20). Serum values of FSCN1 stratified for Gleason score groups were not significantly distinguishable (p = 0.65). A negative correlation (rho = -0.331; p = 0.009) was reported between FSCN1 and age.

Conclusion: Further studies are required to evaluate a possible diagnostic role of FSCN1 in prostate cancer.

Keywords: Fascin-1; biomarker; fascin actin-bundling protein 1; prostate cancer; serum.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure This report was supported by George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Romania, with funds from an internal competition. ‘Fascin an eventual new biomarker in prostate cancer’, is specified with a reference number (9/17800 of 22 December 2015). C Buonerba is a member of the Future Science OA Editorial Board. They were not involved in any editorial decisions related to the publication of this article, and all author details were blinded to the article’s peer reviewers as per the journal’s double-blind peer review policy. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. FSCN1 serum values in study population.
(A) The serum FSCN1 levels in prostate cancer patients (cases) versus controls by applying Mann–Whitney test in order to compare the median FSCN1 serum levels between the two groups. (B) The levels of FSCN1 for Gleason score groups in PCa patients when compared with controls performing Kruskal–Wallis test to determine the statistically significant difference between the medians of Gleason score groups. (C) The negative correlation (Spearman test) between FSCN1 and age for the control group (rho = -0.331; p = 0.009).
Figure 2.
Figure 2.. Violin plots depicting FSCN1 gene expression in different datasets.
(A) Between nontumoral (N) and prostate cancer (PCa) specimens in the indicated datasets. The Y-axis represents the Log2-normalized gene expression (fluorescence intensity values for microarray data or, sequencing reads values obtained after gene quantification with RNA-Seq by expectation maximization (RSEM) and normalization using upper quartile in case of RNAseq). A Student t-test is performed in order to compare the mean gene expression between two groups. (B) Among N, primary tumor and metastatic PCa specimens in the indicated datasets. The Y-axis represents the Log2-normalized gene expression (fluorescence intensity values for microarray data or, sequencing reads values obtained after gene quantification with RSEM and normalization using upper quartile in case of RNAseq). An ANOVA test is performed in order to compare the mean gene expression among two groups. M: Metastatic; N: Nontumoral; PT: Primary tumor.
Figure 3.
Figure 3.. Box plots depicting FSCN1 gene expression in TGCA-prostate adenocarcinoma dataset.
(A) Expression between nontumoral and prostate cancer specimens in the TGCA-prostate adenocarcinoma (PRAD) dataset. (B) In the TGCA-PRAD dataset, based on nodal metastasis status. (C) In the TGCA-PRAD dataset, based on Gleason score. N: Nontumoral; PRAD: Prostate adenocarcinoma; T: Prostate cancer tumor.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018). - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J. Clin. 71(1), 7–33 (2021). - PubMed
    1. Welch HG, Albertsen PC. Reconsidering prostate cancer mortality-the future of PSA screening. N. Engl. J. Med. 382(16), 1557–1563 (2020). - PubMed
    1. Tarantino G, Crocetto F, Di Vito C et al. Association of NAFLD and insulin resistance with non metastatic bladder cancer patients: a cross-sectional retrospective study. J. Clin. Med. 10(2), 346 (2021). - PMC - PubMed
    1. Crocetto F, Boccellino M, Barone B et al. The crosstalk between prostate cancer and microbiota inflammation: nutraceutical products are useful to balance this interplay? Nutrients 12(9), 2648 (2020). - PMC - PubMed